Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
|Slideshows|April 17, 2018
April Research Update: Major Depressive Disorder
Author(s)Mark L. Fuerst
Relapse in MDD is associated with morphologic brain changes; stopping exercise may increase depressive symptoms; and inflammatory biomarkers may predict which treatment-resistant MDD patients benefit from ECT.
Advertisement
Advertisement
Related to this article
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
2
Can Digital Memory Tests Detect Tau-Related Cognitive Change Before Alzheimer Disease?
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Preventing Schizophrenia Relapse in Women: What You Need to Know
5